Cell Cycle

You are here

Cell Cycle

Selina Chen-Kiang, PhD, Principal Investigator

Our goal is to understand the mechanism for cell cycle control of immunity and hematologic malignancies and to translate this knowledge into novel cell cycle-based cancer therapy. Following our discovery that CDK4/CDK6 control B cell immunity, we are investigating CDK control of cancer metabolism and defining genes that mediate clinical response to our hypothesis- driven therapy targeting CDK4/CDK6 in lymphoma and myeloma.

Active Projects

  • Cell cycle control of B cell hemostasis and plasma cell differentiation
  • Cell cycle control of cancer metabolism in lymphoma and myeloma
  • Mechanism-based targeting of CDK4/CDK6 in combination therapy in mantle cell lymphoma and myeloma
  • Defining the mechanism of resistance to therapeutic CDK4/CDK6-based therapy by integrated functional genomics

Active Grants

  • Genomic Analysis: A Phase I Trial of Copanlisib in Patients with Previously Treated Mantle Cell Lymphoma
    PI: Selina Chen-Kiang, PhD
    Bayer Healthcare Pharmaceuticals Sponsored Research Agreement
  • Defining Molecular Biomarkers for CDK4/6- Based Cancer Therapy by RNA sequencing
    PI: Selina Chen-Kiang, PhD
    National Cancer Institute
  • Mechanism-based targeting of CDK4/CDK6 in mantle cell lymphoma
    PI: Selina Chen-Kiang, PhD
    Leukemia & Lymphoma Society
  • Reprogramming mantle cell lymphoma for BTK inhibition by targeting CDK4/CDK6
    PI: Selina Chen-Kiang, PhD
    Lymphoma Research Foundation
  • A Phase I trial of timed sequential administration of PD0332991 followed by ara-C and Mitoxantrone
    PI: Selina Chen-Kiang, PhD
    The Leukemia and Lymphoma Society

Cell Cycle

Selina Chen-Kiang, PhD, Principal Investigator

Our goal is to understand the mechanism for cell cycle control of immunity and hematologic malignancies and to translate this knowledge into novel cell cycle-based cancer therapy. Following our discovery that CDK4/CDK6 control B cell immunity, we are investigating CDK control of cancer metabolism and defining genes that mediate clinical response to our hypothesis- driven therapy targeting CDK4/CDK6 in lymphoma and myeloma.

Active Projects

  • Cell cycle control of B cell hemostasis and plasma cell differentiation
  • Cell cycle control of cancer metabolism in lymphoma and myeloma
  • Mechanism-based targeting of CDK4/CDK6 in combination therapy in mantle cell lymphoma and myeloma
  • Defining the mechanism of resistance to therapeutic CDK4/CDK6-based therapy by integrated functional genomics

Active Grants

  • Genomic Analysis: A Phase I Trial of Copanlisib in Patients with Previously Treated Mantle Cell Lymphoma
    PI: Selina Chen-Kiang, PhD
    Bayer Healthcare Pharmaceuticals Sponsored Research Agreement
  • Defining Molecular Biomarkers for CDK4/6- Based Cancer Therapy by RNA sequencing
    PI: Selina Chen-Kiang, PhD
    National Cancer Institute
  • Mechanism-based targeting of CDK4/CDK6 in mantle cell lymphoma
    PI: Selina Chen-Kiang, PhD
    Leukemia & Lymphoma Society
  • Reprogramming mantle cell lymphoma for BTK inhibition by targeting CDK4/CDK6
    PI: Selina Chen-Kiang, PhD
    Lymphoma Research Foundation
  • A Phase I trial of timed sequential administration of PD0332991 followed by ara-C and Mitoxantrone
    PI: Selina Chen-Kiang, PhD
    The Leukemia and Lymphoma Society

Selected Publications EXPAND ALL ON THIS PAGE

Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.

September 1, 2014
Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P, Mathew S, Vijay P, Eng K, Ali S, Johnson A, Chang B, Ely S, Elemento O, Mason CE, Leonard JP, Chen-Kiang S.

Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.

Cancer Discov. 2014 Sep;4(9):1022-35.

Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P, Mathew S, Vijay P, Eng K, Ali S, Johnson A, Chang B, Ely S, Elemento O, Mason CE, Leonard JP, Chen-Kiang S.

PMID: 25082755; PMCID: PMC4155003

Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity

December 1, 2013
Zhao X., Lwin., T, Zhang X., Huang A., Wang J., Marquez VE., Chen-Kiang S., Dalton WS., Sotomayor E., and Tao J.

Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity

Leukemia. 2013 Dec;27(12):2341-50.

Zhao X, Lwin T, Zhang X, Huang A, Wang J, Marquez VE, Chen-Kiang S, Dalton WS, Sotomayor E, Tao J.

PMID: 23538750; PMCID: PMC4015113

Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1.

June 15, 2013
Chiron D, Martin P, Di Liberto M, Huang X, Ely S, Lannutti BJ, Leonard JP, Mason CE, Chen-Kiang S.

Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1.

Cell Cycle. 2013 Jun 15;12(12):1892-900. 

Chiron D, Martin P, Di Liberto M, Huang X, Ely S, Lannutti BJ, Leonard JP, Mason CE, Chen-Kiang S.

PMID: 23676220

Novel RNA regulatory mechanisms revealed in the epitranscriptome.

March 1, 2013
Selina Chen-Kiang, PhD

Novel RNA regulatory mechanisms revealed in the epitranscriptome.

RNA Biol. 2013 Mar;10(3):342-6. 

Saletore Y, Chen-Kiang S, Mason CE. Novel RNA regulatory mechanisms revealed in the epitranscriptome.

PMID: 23434792; PMCID: PMC3672275

BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma

January 1, 2013
Rossi, A., Mark, T., Jayabalan, D., Christos, P., Zafar, F., Peckle, K., Pearse, R., Chen-Kiang, S., Coleman, M., and Niesvizky, R. BiRd

BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma

Blood. 2013 Mar 14;121(11):1982-5.

Rossi A, Mark T, Jayabalan D, Christos P, Zafar F, Pekle K, Pearse R, Chen-Kiang S, Coleman M, Niesvizky R.

PMID: 23299315; PMCID: PMC3596960

Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-cell lymphomas

October 16, 2012
*Zhang, X., *Zhao, X., Fiskus, W., Lin, J., Lwin,T., Rao, R., Zhang, Y., Chan, J.C., Fu, K., Marquez V.E., Chen-Kiang, S., Moscinski, L.C., Seto, E., Dalton, W.S., Wright, K.L., Sotomayor, E., Bhalla, K., and Tao, J.

Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-cell lymphomas

Cancer Cell. 2012 Oct 16;22(4):506-23. 

*Zhang, X., *Zhao, X., Fiskus, W., Lin, J., Lwin,T.,  Rao, R., Zhang, Y., Chan, J.C., Fu, K., Marquez V.E.,  Chen-Kiang, S., Moscinski, L.C., Seto, E., Dalton, W.S., Wright, K.L., Sotomayor, E., Bhalla, K., and Tao, J.  *Equal contributions

PMID: 23079660; PMCID: PMC3973134

Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.

August 2, 2012
Huang X, Di Liberto M, Jayabalan D, Liang J, Ely S, Bretz J, Shaffer AL 3rd, Louie T, Chen I, Randolph S, Hahn WC, Staudt LM, Niesvizky R, Moore MA, Chen-Kiang S.

Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.

Blood. 2012 Aug 2;120(5):1095-106. 

Huang X, Di Liberto M, Jayabalan D, Liang J, Ely S, Bretz J, Shaffer AL 3rd, Louie T, Chen I, Randolph S, Hahn WC, Staudt LM, Niesvizky R, Moore MA, Chen-Kiang S.

PMID: 22718837; PMCID: PMC3412331

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.

May 17, 2012
Selina Chen-Kiang, PhD

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.

Blood. 2012 May 17;119(20):4597-607.

Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, Yu JQ, Vallabhajosula S, Schoder H, English P, Neuberg DS, Martin P, Millenson MM, Ely SA, Courtney R, Shaik N, Wilner KD, Randolph S, Van den Abbeele AD, Chen-Kiang SY, Yap JT, Shapiro GI.

PMID: 22383795

MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin.

July 1, 2011
Nardiello T, Jungbluth AA, Mei A, Diliberto M, Huang X, Dabrowski A, Andrade VC, Wasserstrum R, Ely S, Niesvizky R, Pearse R, Coleman M, Jayabalan DS, Bhardwaj N, Old LJ, Chen-Kiang S, Cho HJ.

MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin.

Clin Cancer Res. 2011 Jul 1;17(13):4309-19. 

Nardiello T, Jungbluth AA, Mei A, Diliberto M, Huang X, Dabrowski A, Andrade VC, Wasserstrum R, Ely S, Niesvizky R, Pearse R, Coleman M, Jayabalan DS, Bhardwaj N, Old LJ, Chen-Kiang S, Cho HJ.

PMID: 21565982

Noxa mediates p18INK4c cell-cycle control of homeostasis in B cells and plasma cell precursors.

February 17, 2011
Selina Chen-Kiang, PhD

Noxa mediates p18INK4c cell-cycle control of homeostasis in B cells and plasma cell precursors.

Blood. 2011 Feb 17;117(7):2179-88.

Bretz J, Garcia J, Huang X, Kang L, Zhang Y, Toellner KM, Chen-Kiang S.

PMID: 21163929

CDK2 phosphorylation of Smad2 disrupts TGF-beta transcriptional regulation in resistant primary bone marrow myeloma cells

February 15, 2009
Baughn, L., Di Liberto, M., Niesvizky, R., Cho H.J., Jayabalan, D., Lane, J., Liu, F., and Chen-Kiang, S.

CDK2 phosphorylation of Smad2 disrupts TGF-beta transcriptional regulation in resistant primary bone marrow myeloma cells

J Immunol. 2009 Feb 15;182(4):1810-7.

Baughn LB, Di Liberto M, Niesvizky R, Cho HJ, Jayabalan D, Lane J, Liu F, Chen-Kiang S.

PMID: 19201832

A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model

July 1, 2008
*Menu, E., *Garcia, J., Huang, X., Di Liberto, M., Toogood, P., Chen, I., Vanderkerken, K., and Chen-Kiang, S.

A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model

Cancer Res. 2008 Jul 15;68(14):5519-23. 

Menu, E., *Garcia, J., Huang, X., Di Liberto, M., Toogood, P., Chen, I., Vanderkerken, K., and Chen-Kiang, S. *Equal contributions. 

PMID: 18632601

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma

February 1, 2008
Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, Jalbrzikowski J, Pearse RN, Zafar F, Pekle K, Larow A, Lent R, Mark T, Cho HJ, Shore T, Tepler J, Harpel J, Schuster MW, Mathew S, Leonard JP, Mazumdar M, Chen-Kiang S, Coleman M.

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma

Blood. 2008 Feb 1;111(3):1101-9.

Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, Jalbrzikowski J, Pearse RN, Zafar F, Pekle K, Larow A, Lent R, Mark T, Cho HJ, Shore T, Tepler J, Harpel J, Schuster MW, Mathew S, Leonard JP, Mazumdar M, Chen-Kiang S, Coleman M.

PMID: 17989313

Outcome of deferred initial therapy in mantle-cell lymphoma

January 1, 2008
Martin, P., Chadburn, A., Christos, P., Weil, K., Furman, R.R., Ruan, J., Elstrom, R., Niesvizky, R., Ely, S., Di Liberto, M., Melnick, A., Knowles, D.M., Chen-Kiang, S., Coleman, M., and Leonard, J.P.

Outcome of deferred initial therapy in mantle-cell lymphoma

JCO. 27: 1209-13.(2008)

Martin, P., Chadburn, A., Christos, P., Weil, K., Furman, R.R., Ruan, J., Elstrom, R., Niesvizky, R., Ely,  S., Di Liberto, M., Melnick, A., Knowles, D.M., Chen-Kiang, S., Coleman, M., and Leonard, J.P. 

PMID: 19188674

Deletions of CDKN2C in multiple myeloma: biological and clinical implications

January 1, 2008
Leone, P.E., Walker B.A., Jenner, M.W., Chiecchio, L., Degrada, G., Protheroe, R.K.M., Johnson D.C., Dickens, N.J., Brito J.L., Else, M., Gonzalez, D., Ross, F.M., Chen-Kiang, S., Davies, F.E., and Morgan, G.J.

Deletions of CDKN2C in multiple myeloma: biological and clinical implications

Clin Cancer Res. 2008 Oct 1;14(19):6033-41.

Leone PE, Walker BA, Jenner MW, Chiecchio L, Dagrada G, Protheroe RK, Johnson DC, Dickens NJ, Brito JL, Else M, Gonzalez D, Ross FM, Chen-Kiang S, Davies FE, Morgan GJ.

PMID: 18829482; PMCID: PMC2581792

Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies

January 1, 2008
Martin, P., Chadburn, A., Christos, P., Furman, R., ,Ruan, J., Joyce, M.A., Fusco, E., Glynn, P., Elstrom, R., Niesvizky, R., Feldman, E.J., Shore, T.B., Schuster, M.W., Ely, S., ,Knowles, D.M., Chen-Kiang, S., Coleman, M., and Leonard, P.

Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies

Ann Oncol. 2008 Jul;19(7):1327-30.

Martin P, Chadburn A, Christos P, Furman R, Ruan J, Joyce MA, Fusco E, Glynn P, Elstrom R, Niesvizky R, Feldman EJ, Shore TB, Schuster MW, Ely S, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP.

PubMed PMID: 18349031

A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6

August 1, 2006
Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R, Niesvizky R, Cho H, Ely S, Moore MA, Chen-Kiang S.

A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6

Cancer Res. 2006 Aug 1;66(15):7661-7.

Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R, Niesvizky R, Cho H, Ely S, Moore MA, Chen-Kiang S. 

PMID: 16885367.

Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma

January 1, 2005
*Ely, S., *Di Liberto, M., Niesvizky, R., Baughn, L. B., Cho, H. J., Hatada, E. N., Knowles, D. M., Lane, J., and Chen-Kiang, S.

Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma

Cancer Res. 2005 Dec 15;65(24):11345-53.

*Ely, S., *Di Liberto, M., Niesvizky, R., Baughn, L. B., Cho, H. J., Hatada, E. N., Knowles, D. M., Lane, J., and Chen-Kiang, S. *Equal contributions. 

PMID: 16357141

The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation

January 1, 2005
Jungbluth, A. A., Ely, S., DiLiberto, M., Niesvizky, R., Williamson, B., Frosina, D., Chen, Y. T., Bhardwaj, N., Chen-Kiang, S., Old, L. J., and Cho, H. J.

The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation

Blood. 2005 Jul 1;106(1):167-74. 

Jungbluth, A. A., Ely, S., DiLiberto, M., Niesvizky, R., Williamson, B., Frosina, D., Chen, Y. T., Bhardwaj, N., Chen-Kiang, S., Old, L. J., and Cho, H. J.

PMID: 15761016

Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1

December 21, 2004
Huang, X., Di Liberto, M., Cunningham, A. F., Kang, L., Cheng, S., Ely, S., Liou, H. C., Maclennan, I. C., and Chen-Kiang, S.

Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1

Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17789-94. 

Huang, X., Di Liberto, M., Cunningham, A. F., Kang, L., Cheng, S., Ely, S., Liou, H. C., Maclennan, I. C., and Chen-Kiang, S.

PMID: 15591344

AID is required for c-myc/IgH chromosome translocations in vivo

August 20, 2004
Ramiro, A. R., Jankovic, M., Eisenreich, T., Difilippantonio, S., Chen-Kiang, S., Muramatsu, M., Honjo, T., Nussenzweig, A., and Nussenzweig, M. C.

AID is required for c-myc/IgH chromosome translocations in vivo

Cell. 2004 Aug 20;118(4):431-8.

Ramiro, A. R., Jankovic, M., Eisenreich, T., Difilippantonio, S., Chen-Kiang, S., Muramatsu, M., Honjo, T., Nussenzweig, A., and Nussenzweig, M. C.

PMID: 15315756

NF-kappa B1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-kappa B2 p100 to p52 in quiescent mature B cells

January 1, 2003
Hatada, E. N., Do, R. K., Orlofsky, A., Liou, H. C., Prystowsky, M., MacLennan, I. C., Caamano, J., and Chen-Kiang, S.

NF-kappa B1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-kappa B2 p100 to p52 in quiescent mature B cells

J Immunol. 2003 Jul 15;171(2):761-8.

Hatada, E. N., Do, R. K., Orlofsky, A., Liou, H. C., Prystowsky, M., MacLennan, I. C., Caamano, J., and Chen-Kiang, S.

PMID: 12847243

TRAIL/Apo-2 ligand induces primary plasma cell apoptosis

January 1, 2002
Ursini-Siegel, J., Zhang, W., Altmeyer, A., Hatada, E. N., Do, R. K., Yagita, H., and Chen-Kiang, S.

TRAIL/Apo-2 ligand induces primary plasma cell apoptosis

J Immunol. 2002 Nov 15;169(10):5505-13.

Ursini-Siegel, J., Zhang, W., Altmeyer, A., Hatada, E. N., Do, R. K., Yagita, H., and Chen-Kiang, S.

PMID: 12421926

CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells

January 1, 2002
Tourigny, M. R., Ursini-Siegel, J., Lee, H., Toellner, K. M., Cunningham, A. F., Franklin, D. S., Ely, S., Chen, M., Qin, X. F., Xiong, Y., MacLennan, I.C.M and Chen-Kiang, S.

CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells

Immunity. 2002 Aug;17(2):179-89.

Tourigny, M. R., Ursini-Siegel, J., Lee, H., Toellner, K. M., Cunningham, A. F., Franklin, D. S., Ely, S., Chen, M., Qin, X. F., Xiong, Y., MacLennan, I.C.M and Chen-Kiang, S. 

PMID: 12196289

Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response

January 1, 2000
Do, R. K., Hatada, E., Lee, H., Tourigny, M. R., Hilbert, D., and Chen-Kiang, S.

Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response

J Exp Med. 2000 Oct 2;192(7):953-64.

Do, R. K., Hatada, E., Lee, H., Tourigny, M. R., Hilbert, D., and Chen-Kiang, S.

PMID: 11015437

Interaction and functional interference of C/EBPbeta with octamer factors in immunoglobulin gene transcription

January 1, 2000
Hatada, E. N., Chen-Kiang, S., and Scheidereit, C.

Interaction and functional interference of C/EBPbeta with octamer factors in immunoglobulin gene transcription

Eur J Immunol. 2000 Jan;30(1):174-84.

Hatada, E. N., Chen-Kiang, S., and Scheidereit, C. (2000).

PMID: 10602039

CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis

January 1, 1998
Franklin, D. S., Godfrey, V. L., Lee, H., Kovalev, G. I., Schoonhoven, R., Chen-Kiang, S., Su, L., and Xiong, Y.

CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis

Genes Dev. 1998 Sep 15;12(18):2899-911.

Franklin, D. S., Godfrey, V. L., Lee, H., Kovalev, G. I., Schoonhoven, R., Chen-Kiang, S., Su, L., and Xiong, Y. (1998).

PMID: 9744866

Reversal of EBV immortalization precedes apoptosis in IL-6-induced human B cell terminal differentiation.

January 1, 1997
Altmeyer, A., Simmons, R. C., Krajewski, S., Reed, J. C., Bornkamm, G. W., and Chen-Kiang, S.

Reversal of EBV immortalization precedes apoptosis in IL-6-induced human B cell terminal differentiation.

Immunity. 1997 Nov;7(5):667-77.

Altmeyer, A., Simmons, R. C., Krajewski, S., Reed, J. C., Bornkamm, G. W., and Chen-Kiang, S.

PMID: 9390690

Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6

January 1, 1997
Morse, L., Chen, D., Franklin, D., Xiong, Y., and Chen-Kiang, S.

Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6

Immunity. 1997 Jan;6(1):47-56.

Morse, L., Chen, D., Franklin, D., Xiong, Y., and Chen-Kiang, S.

PMID: 9052836

Retinoblastoma protein directly interacts with and activates the transcription factor NF-IL6

January 1, 1996
Chen, P. L., Riley, D. J., Chen-Kiang, S., and Lee, W. H.

Retinoblastoma protein directly interacts with and activates the transcription factor NF-IL6

Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):465-9.

Chen, P. L., Riley, D. J., Chen-Kiang, S., and Lee, W. H

PMID: 8552662

Requirement of serine phosphorylation for formation of STAT-promoter complexes.

January 1, 1995
Zhang, X., Blenis, J., Li, H. C., Schindler, C., and Chen-Kiang, S.

Requirement of serine phosphorylation for formation of STAT-promoter complexes.

Science. 1995 Mar 31;267(5206):1990-4.

Zhang, X., Blenis, J., Li, H. C., Schindler, C., and Chen-Kiang, S.

PMID: 7701321

General Contact

Selina Chen-Kiang, PhD
Professor of Pathology and Laboratory Medicine
Weill Cornell Medical College
1300 York Avenue, C-316
New York, NY 10065
Tel: 212-746-6442
Fax: 212-746-7996
sckiang@med.cornell.edu

BACK TO TOP